N. D. Beerman

Biography

Noah Beerman has been an executive in the biopharmaceutical industry for more than 25 years, beginning at Repligen, Sandoz, Curis, and Technology Management & Funding. Mr. Beerman then joined Indevus Pharmaceuticals, where he was responsible for multiple licensing, co-promotion and M&A agreements, establishing an industry-leading profile in corporate development as Chief Business Officer for the company. Subsequently, he was President, CEO and Director of RXI Pharmaceuticals (now Galena BioPharma), and until 2013 Executive Vice President and Chief Operating Officer at Coronado Biosciences. Most recently, Mr. Beerman has served as an executive consultant in the biopharmaceutical industry, and Director on the Board of Trasir Therapeutics. Noah Beerman has been an executive in the biopharmaceutical industry for more than 25 years, beginning at Repligen, Sandoz, Curis, and Technology Management & Funding. Mr. Beerman then joined Indevus Pharmaceuticals, where he was responsible for multiple licensing, co-promotion and M&A agreements, establishing an industry-leading profile in corporate development as Chief Business Officer for the company. Subsequently, he was President, CEO and Director of RXI Pharmaceuticals (now Galena BioPharma), and until 2013 Executive Vice President and Chief Operating Officer at Coronado Biosciences. Most recently, Mr. Beerman has served as an executive consultant in the biopharmaceutical industry, and Director on the Board of Trasir Therapeutics.

Research Interest

biopharmaceutical